Compare EPR Properties (EPR) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
EPR Properties vs Novo Nordisk A/S — how do they compare? EPR Properties trades at $61.2 (market cap $4.58B), while Novo Nordisk A/S trades at $46.28 (market cap $207.85B). The key difference: Novo Nordisk A/S is far larger — about 45.4× EPR Properties's market cap, and EPR Properties pays the higher dividend (6.22%). Which is the better fit depends on your goals.
| EPR | NVO | |
|---|---|---|
Market Cap | $4.58B | $207.85B |
Sector | Real Estate | Health |
52-Week High | $64.32 | $63.98 |
52-Week Low | $48.71 | $35.29 |
Enterprise Value | $8.09B | $222.55B |
Dividend Yield | 6.22% | 3.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EPR Properties trades at $60.81, up 0.68% on the day, with a bearish technical signal but strong fundamentals including a 91.41% gross margin and recent Q2 2026 FFO beat. The company raised full-year guidance after deploying $440 million in investments at an 8.5% cap rate, signaling growth momentum. Dividend payments remain consistent at $0.31 monthly, supported by a conservative 65% AFFO payout ratio.
Outlook is mixed: analyst consensus is a Buy with a $65.30 target (7% upside), but technicals and some sentiment caution near-term. Key risks include theater exposure and rising interest rates. The stock offers a 6% yield with potential for dividend growth, balancing income and moderate appreciation prospects.
Novo Nordisk (NVO) trades at $46.465, down 2.65% today, with a neutral technical signal. The stock shows strong fundamentals, including a P/E of 11.62, net income margin of 35.35%, and consistent earnings beats in recent quarters. Recent news highlights competitive pressures from Eli Lilly and mixed investor reactions to Q2 2026 results, despite an upwardly revised full-year outlook.
Outlook remains positive due to robust GLP-1 drug demand and profitability, but risks include pricing pressure and competition. Analysts are predominantly bullish (57.9% buy ratings), supporting a favorable long-term view despite near-term volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About EPR Properties
EPR Properties is a REIT specializing in experiential real estate, including movie theaters and leisure destinations like ski resorts and water parks across the US and Canada.
Read more on EPR →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
